See more : Huntington Bancshares Incorporated (0J72.L) Income Statement Analysis – Financial Results
Complete financial analysis of PharmaCyte Biotech, Inc. (PMCB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PharmaCyte Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- GLG Corp Ltd (GLE.AX) Income Statement Analysis – Financial Results
- AFC Gamma, Inc. (AFCG) Income Statement Analysis – Financial Results
- Amrutanjan Health Care Limited (AMRUTANJAN.BO) Income Statement Analysis – Financial Results
- Movella Holdings Inc. (MVLA) Income Statement Analysis – Financial Results
- Industrial and Commercial Bank of China Limited (ICK.VI) Income Statement Analysis – Financial Results
PharmaCyte Biotech, Inc. (PMCB)
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.16K | 66.56K | 126.00K | 262.93K | 653.13K | 1.19M | 1.17M | 537.04K | 86.37K | 2.38K | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.62K | 19.38K | 32.10K | 228.66K | 427.41K | 266.20K | 171.01K | 0.00 | 41.40K | 780.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K | 47.18K | 93.89K | 34.27K | 225.72K | 923.75K | 998.65K | 537.04K | 44.97K | 1.60K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 20.89% | 70.88% | 74.52% | 13.03% | 34.56% | 77.63% | 85.38% | 100.00% | 52.07% | 67.27% | 0.00% | 0.00% |
| Research & Development | 407.43K | 468.54K | 690.94K | 916.25K | 301.22K | 460.05K | 2.00M | 1.18M | 1.41M | 3.48M | 323.50 | 0.00 | 0.00 | 9.21K | 492.46K | 473.51K | 412.88K | 133.84K | 119.01K | 1.11M | 1.41M | 0.00 | 0.00 |
| General & Administrative | 4.79M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 9.99M | 18.11M | 1.58M | 1.99M | 462.22K | 1.24M | 5.20M | 0.00 | 0.00 | 6.56M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 230.50K | 872.20K | 106.41K | 11.15K | 10.83K | 411.72K | 594.34K | 0.00 | 0.00 | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.12M | 5.99M | 3.70M | 2.71M | 3.53M | 3.64M | 4.98M | 3.26M | 4.67M | 10.22M | 18.98M | 1.69M | 2.00M | 473.05K | 1.65M | 5.79M | 4.26M | 4.47M | 7.75M | 3.10M | 313.95K | 32.13K | 0.00 |
| Other Expenses | 0.00 | 202.00K | -4.28K | -1.19K | -40.00 | 33.40K | 152.59K | 2.52M | 10.54K | 3.34M | -5.90M | 2.59K | 1.22M | 103.90K | 0.00 | 4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.85K |
| Operating Expenses | 8.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.69M | 2.00M | 482.25K | 2.14M | 6.27M | 4.67M | 4.61M | 7.87M | 4.21M | 1.72M | 32.13K | 29.85K |
| Cost & Expenses | 6.52M | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 13.70M | 18.98M | 1.70M | 2.02M | 514.36K | 2.37M | 6.70M | 4.94M | 4.78M | 7.87M | 4.25M | 1.72M | 32.13K | 29.85K |
| Interest Income | 3.40M | 1.94M | 157.65K | 3.05 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09K | 0.00 | 0.00 | 0.00 | 0.00 | 14.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 509.00 | 3.05K | 453.00 | 0.00 | 0.00 | 1.54K | 1.19K | 4.94K | 21.05K | 154.42K | 241.25K | 171.66K | 292.56K | 27.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 6.46M | 4.39M | 3.62M | 3.83M | 4.10M | 6.98M | 4.44M | 6.07M | 492.05K | -5.89M | 2.59K | 24.66K | 40.69K | 114.91K | 28.83K | 6.38K | 1.35K | 488.00 | 23.26K | 0.00 | 0.00 | 0.00 |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -3.83M | 0.00 | 0.00 | -4.44M | 0.00 | -9.92M | -27.23M | -1.68M | -1.63M | -388.36K | -2.11M | -5.99M | -3.78M | -3.61M | -7.33M | -1.72M | -1.73M | -32.13K | -29.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,830.35% | -3,328.88% | 388.91% | 607.14% | -922.67% | -308.99% | -308.83% | -1,049.52% | -4,810.34% | -72,213.26% | 0.00% | 0.00% |
| Operating Income | -6.52M | -6.46M | -4.39M | -3.62M | -3.83M | -4.10M | -6.98M | -4.44M | -6.07M | -13.70M | -18.98M | -1.68M | -1.95M | -388.36K | -2.11M | -6.04M | -3.75M | -3.61M | -7.34M | -4.16M | -1.72M | -32.13K | -29.85K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,851.65% | -2,928.55% | -308.23% | -802.09% | -925.09% | -315.07% | -308.42% | -1,365.85% | -4,819.57% | -72,213.26% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.85M | 2.14M | 152.85K | 71.75K | -493.00 | 33.40K | 152.59K | -1.54K | 9.35K | 2.84M | -8.27M | 86.26K | 49.87K | -837.69K | -3.88M | 471.00 | -42.72K | -6.79K | -1.76M | -114.04K | 1.73M | 0.00 | 0.00 |
| Income Before Tax | 333.76K | -4.32M | -4.24M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.66M | -1.23M | -5.70M | -6.03M | -3.82M | -3.60M | -9.03M | -4.15M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,491.16% | -973.08% | -2,167.62% | -923.10% | -320.62% | -307.90% | -1,682.09% | -4,801.87% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -153.36K | 3.05K | 453.00 | -33.40K | -152.59K | -4.44K | -4.88K | 4.94K | 19.96K | 154.42K | -49.87K | 1.01M | 3.88M | -471.00 | 42.72K | 6.79K | 2.05M | 114.04K | 1.72M | 32.13K | 29.85K |
| Net Income | 333.76K | -4.32M | -4.09M | -3.55M | -3.83M | -4.07M | -6.83M | -4.44M | -6.06M | -10.85M | -27.25M | -1.60M | -1.90M | -1.40M | -5.99M | -6.04M | -3.79M | -3.61M | -9.39M | -4.28M | -1.72M | -32.13K | -29.85K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -13,142.29% | -2,853.62% | -1,109.32% | -2,278.89% | -925.02% | -318.66% | -309.00% | -1,747.61% | -4,951.60% | -72,375.79% | 0.00% | 0.00% |
| EPS | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.89 | -12.09 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| EPS Diluted | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 | -10.57 | -7.88 | -12.08 | -23.11 | -70.06 | -5.43 | -7.60 | -5.98 | -29.81 | -44.86 | -33.86 | -33.36 | -102.95 | -61.74 | -27.40 | -0.55 | -0.51 |
| Weighted Avg Shares Out | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 645.76K | 563.54K | 501.60K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
| Weighted Avg Shares Out (Dil) | 9.58M | 19.49M | 15.52M | 1.45M | 903.81K | 733.40K | 646.08K | 563.82K | 501.85K | 469.79K | 389.01K | 294.12K | 249.97K | 233.68K | 200.97K | 134.68K | 112.01K | 108.34K | 91.16K | 69.27K | 62.95K | 58.70K | 58.70K |
MyMD Pharmaceuticals Secures Strategic Investments
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in...
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions....
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad...
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the...
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) provides an update on its investigation of its Cell-in-a-Box technology and initial next steps in development. Following a comprehensive scientific review of amassed data, the Company is in the...
PharmaCyte Biotech Announces Final Results of Tender Offer
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces the final results of its previously announced tender offer to acquire up to 7,750,000 million shares of the Company's common stock, par value $0.001 per share, at...
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it...
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) today announces a cash tender offer for up to 7,750,000 shares at $3.25 per share, less any applicable withholding taxes and without interest. The Company also announces that it...
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box® for potential development of cellular therapies for cancer, diabetes and malignant ascites, announced today that its Board of...
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
LAS VEGAS--( BUSINESS WIRE )--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Cell-in-a-Box ® for potential development of cellular therapies for cancer, diabetes and malignant ascites, announced today that...
Source: https://incomestatements.info
Category: Stock Reports